UY32444A - Composiciones y procedimientos para terapia extendida con aminopiridinas - Google Patents

Composiciones y procedimientos para terapia extendida con aminopiridinas

Info

Publication number
UY32444A
UY32444A UY0001032444A UY32444A UY32444A UY 32444 A UY32444 A UY 32444A UY 0001032444 A UY0001032444 A UY 0001032444A UY 32444 A UY32444 A UY 32444A UY 32444 A UY32444 A UY 32444A
Authority
UY
Uruguay
Prior art keywords
compositions
aminopiridins
procedures
extended therapy
therapy
Prior art date
Application number
UY0001032444A
Other languages
English (en)
Inventor
Andrew R Blight
Cohen Ron
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562065&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32444(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of UY32444A publication Critical patent/UY32444A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente métodos y composiciones relacionadas al uso de aminopiridinas, tales como 4-aminopiridina, para uso en una manera terapéuticamente efectiva por pacientes con una afección desmielinante, tal como esclerosis múltiple.
UY0001032444A 2009-02-11 2010-02-11 Composiciones y procedimientos para terapia extendida con aminopiridinas UY32444A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15167909P 2009-02-11 2009-02-11
US25956309P 2009-11-09 2009-11-09
US28587209P 2009-12-11 2009-12-11
US28895309P 2009-12-22 2009-12-22
US29925910P 2010-01-28 2010-01-28

Publications (1)

Publication Number Publication Date
UY32444A true UY32444A (es) 2010-09-30

Family

ID=42562065

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001032445A UY32445A (es) 2009-02-11 2010-02-11 Composicion y procedimiento para usar aminopiridinas
UY0001032444A UY32444A (es) 2009-02-11 2010-02-11 Composiciones y procedimientos para terapia extendida con aminopiridinas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001032445A UY32445A (es) 2009-02-11 2010-02-11 Composicion y procedimiento para usar aminopiridinas

Country Status (22)

Country Link
US (3) US20120029035A1 (es)
JP (1) JP2012517449A (es)
KR (3) KR20120000560A (es)
CN (2) CN102046174A (es)
AR (1) AR075413A1 (es)
AU (2) AU2010213663A1 (es)
BR (2) BRPI1000031A2 (es)
CA (1) CA2751581A1 (es)
CL (1) CL2011001927A1 (es)
CO (1) CO6440534A2 (es)
EA (1) EA022755B1 (es)
EC (1) ECSP11011311A (es)
IL (1) IL214500A0 (es)
MX (1) MX2011008485A (es)
NI (1) NI201100155A (es)
NZ (1) NZ595046A (es)
PE (1) PE20120791A1 (es)
SG (2) SG173641A1 (es)
TN (1) TN2011000403A1 (es)
TW (2) TW201032809A (es)
UY (2) UY32445A (es)
WO (2) WO2010093839A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20150111930A1 (en) * 2013-10-23 2015-04-23 Afgin Pharma, Llc Topical regional neuro-affective therapy
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
CN102442942A (zh) * 2010-10-08 2012-05-09 天津和美生物技术有限公司 4-氨基吡啶的多晶型物及其制备和应用
US20130030025A1 (en) * 2011-01-28 2013-01-31 Wessel Thomas C Use of potassium channel blockers to treat cerebral palsy
CA2864340A1 (en) * 2012-02-13 2013-08-22 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
WO2015118529A1 (en) * 2014-02-04 2015-08-13 Optimata Ltd. Method and system for prediction of medical treatment effect
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
CN106511293B (zh) * 2015-09-11 2020-08-04 法德生技药品股份有限公司 含有达方吡啶的缓释口服制剂及其用途
WO2022124946A1 (ru) * 2020-12-10 2022-06-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение
CN112914884B (zh) * 2021-01-19 2022-02-11 重庆火后草科技有限公司 通过稳态时长置信度测量睡眠状态下的体重值的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
AR075413A1 (es) 2011-03-30
CN102046174A (zh) 2011-05-04
EA201171043A1 (ru) 2012-02-28
KR20170034452A (ko) 2017-03-28
AU2016219650A1 (en) 2016-09-15
TW201032809A (en) 2010-09-16
US20150313886A1 (en) 2015-11-05
MX2011008485A (es) 2011-11-04
SG10201609184PA (en) 2016-12-29
NI201100155A (es) 2012-02-16
PE20120791A1 (es) 2012-07-08
UY32445A (es) 2010-09-30
WO2010093838A1 (en) 2010-08-19
CA2751581A1 (en) 2010-08-19
BRPI1000030A2 (pt) 2018-02-14
CL2011001927A1 (es) 2012-07-20
JP2012517449A (ja) 2012-08-02
CO6440534A2 (es) 2012-05-15
IL214500A0 (en) 2011-09-27
AU2016219650B2 (en) 2018-05-10
EA022755B1 (ru) 2016-02-29
NZ595046A (en) 2013-10-25
BRPI1000031A2 (pt) 2018-02-14
KR20180114250A (ko) 2018-10-17
CN101896182A (zh) 2010-11-24
TN2011000403A1 (en) 2013-03-27
US20120029035A1 (en) 2012-02-02
WO2010093839A1 (en) 2010-08-19
AU2010213663A1 (en) 2011-09-29
AU2016219650C1 (en) 2018-08-23
TW201034665A (en) 2010-10-01
KR20120000560A (ko) 2012-01-02
US20170319562A1 (en) 2017-11-09
SG173641A1 (en) 2011-09-29
ECSP11011311A (es) 2011-10-31

Similar Documents

Publication Publication Date Title
UY32444A (es) Composiciones y procedimientos para terapia extendida con aminopiridinas
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
MX2022007264A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
IN2015DN01119A (es)
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
PH12015500746A1 (en) Benzamides
IN2014DN06104A (es)
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2013185764A3 (en) Pharmaceutical compositions for combination therapy
EA201300733A1 (ru) Рекомбинантные микобактерии в качестве вакцины
UY33833A (es) Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
AR078323A1 (es) Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
UA114486C2 (uk) Застосування 4-амінопіридину у лікуванні пов'язаної з інсультом сенсорно-рухової недостатності
WO2013190509A3 (en) Preparation of intermediates of boceprevir
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
MX2012012489A (es) Preparacion de polipeptidos y sales de los mismos.
EA201590782A1 (ru) Оксирановые амины
IN2014DN03298A (es)
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
MX2013005624A (es) Nuevos derivados de indolizina, su preparacion y su aplicacion en terapeutica.
UA104307C2 (ru) Способ продолжительной терапии с применением 4-аминопиридина

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181218